Industry Advisory Board
Harper Cancer Research Institute

Gaylene Anderson, M.B.A.
US Director – Contracts and Alliance Management
Boehringer Ingelheim Pharmaceuticals

Gaylene is the US Director of Contracts and Alliance Management for Boehringer Ingelheim - managing research contracts and licensing opportunities for BI with US partners. As Director of the Notre Dame/Cleveland Clinic Innovations Alliance Program and Senior Innovations Officer for the Cleveland Clinic, Gaylene was the on-site liaison between ND and CC. She accelerated select technologies through the commercialization process, created new ventures, and identified complementary research opportunities between ND scientists and CC clinicians. She has a strong focus on BD, licensing, IP management, contract negotiations, alliance management, and entrepreneurship activities. She has created over a dozen start-up companies, developed relationships with investor groups around the U.S., raised private equity for startups, and is an expert in negotiating license and sponsored research deals.

In her work with CC and university systems, Gaylene has won leadership awards for her work with faculty and students in business plan competitions – including "Mentor of the Year" for ND in 2015. Under Gaylene's leadership, faculty and student teams have won or placed as finalists in the World's Best Technology Showcase, the Licensing Executive Society Invention Competition, the Global Venture Labs Investment Competition, the Asia Venture Challenge, and university business plan competitions all over the US. Previously, Gaylene was a Senior Licensing Associate for the University of Idaho, managing all life science IP for the University system, and served as the liaison for the state commodity commissions. Earlier in her career, Gaylene managed IP and economic development activities for the School of Medicine and Cancer Research Center at the University of Hawaii.

As an entrepreneur herself, Gaylene created the highly successful Waterproof Kids® learn-to-swim DVD series, which has won numerous parent and media awards, and is sold all around the world.

Dr. Richard "Rick" Connell, Ph.D.
Vice President – External Research Solutions
Pfizer

Rick Connell started at Pfizer in Groton, CT, as Director of Cancer Medicinal Chemistry in 1999. He has held several positions in the company, including a year in Shanghai, China, as a vice president responsible for Asia research. His current role is with Pfizer Global Research & Development as Vice President of External Research Solutions. This group, previously referred to as Research Outsourcing, manages the pre-clinical services needs of World Wide Pfizer Research organization. While focused on Contract Research Organization (CRO) services, we also help integrate the IT and logistical support for external academic, government, and biotech collaborations that serve the Research Units at

Pfizer. Prior to joining Pfizer, he conducted research for Bayer as a Research Scientist, a Lab Head in the Cardiovascular Division, and as the Director of Diabetes and Obesity Chemistry. Rick has is a Ph.D. level Oncology clinical research scientist with industry experience in Immuno Oncology translational research, focused on clinical trial design and implementation. He has held multiple roles fostering external and internal collaborations and is an effective scientific communicator, with substantial relationships with academic Key Opinion Leaders. He has a strong background in scientific/medical data interpretation, and experience in all stages of drug development.

Rick studied at the Kungliga Tekniska Högskolan (KTH) Royal Institute of Technology, in Stockholm, Sweden, and received his PhD in organic chemistry in the laboratory of Professor Paul Helquist at the University of Notre Dame. After graduation, he was an NIH Post Doctoral Investigator under the direction of Professor E. J. Corey at Harvard University.

Dr. Behrad Derakhshan, Ph.D.

Vice President – Business Development
Therachon

Behrad is Vice President, Head of Business Development at Therachon AG, a global biotech focused on developing medicines for rare, genetic diseases that currently have no available treatments. Behrad has 10 years of experience in the rare/ultra-rare disease space, most recently as a Director at Alexion Pharmaceuticals responsible for Business Development and Strategic Evaluation. In this role, he reviewed and evaluated numerous opportunities for potential in-licensing or acquisition. Prior to this role, Behrad served as the Director of New Products, leading Global Commercial Insights and Analytics, also at Alexion, where he provided commercial support for both early stage development and late stage life cycle programs for Alexion's internal portfolio as well as external Business Development opportunities.

Behrad went to Alexion after spending several years in life science consulting, first as a Senior Consultant at Easton Associates and then as an Associate Director at Navigant Consulting, Inc. Behrad provided consulting services to numerous Top 20 pharmaceutical, medical device and biotechnology companies, including business development/opportunity searches, corporate and commercial strategies, payer/reimbursement strategies and strategic product development.

Behrad earned his Ph.D. in pharmacology and biochemistry from Cornell University, Weill Graduate School of Medical Sciences and was a Postdoctoral Associate in the Interdepartmental Program in Vascular Biology and Therapeutics at the Yale University School of Medicine. He received a First Class Honors BSc. In Biochemistry from the University of Surrey. He has presented at multiple international meetings and authored several peer-reviewed research articles and book chapters. In 2006, he was the recipient of an "International Young Investigator Award" for research performed during his graduate degree.

Dr. Erik Eglite, D.P.M., J.D., M.B.A.

Senior Vice President, General Counsel and Chief Corporate Compliance Officer
Aurinia Pharmaceuticals

In his role at Aurinia Pharmaceuticals, Erik is responsible for legal compliance matters for the company. Prior to joining Aurinia, Dr. Eglite served as Vice President, Chief Compliance Officer and Corporate Counsel for Marathon Pharmaceuticals, Vice President, Chief Compliance Officer and Corporate Counsel for Lundbeck Pharmaceuticals, and Vice President, Chief Compliance Officer and Corporate Counsel for Ovation Pharmaceuticals and Global Chief Compliance Officer for Aspreva Pharmaceuticals. Erik has been involved with the clinical development, launch and commercialization of 12 drugs and drug programs. He is a nationally recognized and frequent speaker on pharmaceutical law. Before entering the pharmaceutical industry, Erik worked as Assistant General Counsel for the Department of Human Services and as a medical malpractice/product liability defense litigation and intellectual property/patent attorney for Querry & Harrow in Chicago, Illinois. He is a licensed podiatric physician and surgeon and is registered to practice before the United States Patent and Trademark Office, the United States Court of Appeals for the Federal Circuit, the United States Court of Appeals for the District of Columbia Circuit and the United States Seventh Circuit Court of Appeals.

Erik has a M.B.A. from the University of Notre Dame. He also holds a B.S. in Biology, a B.A. in History, M.Sc. Cand. in Chemistry, and a J.D. from Loyola University of Chicago. Erik graduated from Des Moines University Iowa Medical School with a Doctorate in Podiatric Medicine and Surgery, after which he completed his residency training at Michigan Health Medical Center Hospital. He also completed his medical/surgical externships at the University of Chicago, Department of Surgery, Division of Vascular Surgery and Northwestern University Columbus Cabrini Hospital, Department of Orthopedic/Podiatric Surgery. He has a graduate certificate in Pharmaceutical & Medical Device Law from Seton Hall School of Law, an Executive Certificate in Corporate Governance from Northwestern University Kellogg School of Management and an Executive Certificate in Business Administration from the University of Notre Dame.

Dr. Monica Kolinsky, Ph.D., J.D.

Associate Counsel
Wiggin and Dana

Monica Kolinsky, Ph.D. is an Associate in the Corporate Department at Wiggin and Dana and is a member of the Life Sciences Practice Group. Before joining Wiggin and Dana, Monica was of counsel at Grimes & Yvon LLP, in New York, NY, where she drafted and prosecuted patent applications in the areas of life sciences and biotechnology and drafted and negotiated agreements related to intellectual property and research materials. She was previously a licensing officer for Medical Research Council Technology in London and was an Associate and Technology Specialist at WilmerHale in NewYork.

Monica earned her J.D. from New York Law School, *cum laude*, and her Ph.D. in Pharmacology from Cornell University, Weill Graduate School of Medical Sciences. She earned her B.S, *cum laude*, from Moravian College with a major in Biology and minor in Chemistry. She was also a Carolina Summer Research Fellow in the Pharmacology department at the University of North Carolina. Monica is admitted to practice law in the state of New York and is registered to practice before the United States Patent and Trademark Office.

Dr. John "Jay" McGill, Ph.D.

Senior Director, LRL Science and Technology Partnerships
Eli Lilly and Company

Jay McGill, Ph.D. is a Senior Director at Eli Lilly and Company in Lilly Research Laboratories Operations responsible for Science and Technology Partnerships. In this role, Jay serves as the interface between academic institutions and scientists within Lilly Research Labs. In addition, Dr. McGill oversees Lilly's portfolio of research based Public Private Partnerships and Consortium Participation. Dr. McGill brings a vast experience in collaboration, partnership, research operations, and venture to this critical interface with the academic research community.

After receiving a B.S. in Chemistry from the University of Georgia and a Ph.D. in Organic Chemistry from Indiana University, Jay joined Eli Lilly and Company in 1990 as a Senior Scientist in the Chemical Process Development Group. In 1998, he joined the Discovery Chemistry Research and Technologies organization where he held a number of positions including Head of the Custom Synthesis Lab, Director of the Discovery Chemistry Synthesis Group and Senior Director of Global Chemistry Sourcing. In 2008, as part of reorganization within Lilly Research Laboratories all of the research based sourcing groups (chemistry, *in vitro* and *in vivo* biology, tox and ADME) were consolidated under Jay's leadership as Senior Director of External Research Operations. Jay has more than 25 years of experience in pharmaceutical research and development, research collaborations, and outsourcing management. During his career he has been instrumental in creating and developing Eli Lilly's collaborations in Asia, and establishing operations to support an external network of research based outsourcing partners and alliances. Jay is known for his leadership in the pioneering of novel and transformational partnership models.

Dr. Kathryn Packman, PhD

Senior Scientific Director – Tumor Biology
The Janseen Pharmaceutical Companies of Johnson & Johnson

Kathryn Packman is Scientific Director of Oncology Collaborations at Janssen Research & Development, LLC. From the Johnson & Johnson Innovation Center in Boston, she leads academic and biotechnology research collaborations for the Oncology therapeutic area located on the East Coast of the U.S. In this role, she brings cutting-edge technologies and deep biological insight to accelerate development of transformative medicines for cancer patients. Kathryn is an in vivo pharmacology leader with extensive preclinical drug discovery experience. Kathryn was head of preclinical oncology research at the Roche Translational and Clinical Research Center, where she defined the small molecule externalization strategy and delivered preclinical research support through academic and biotechnology alliances.

Prior to that, she led preclinical tumor biology at Roche Pharmaceuticals for 10 years, where her laboratory examined drug efficacy and biological mechanisms of action in vivo. This work culminated in the advancement of ten drugs with companion biomarkers into clinical investigation, including CDK inhibitor R547, multi-kinase inhibitor R1530, MEK 1/2 inhibitor RO5068760, Gamma Secretase inhibitor RG4733, anti-PlGF MAb RG7334, anti-Tweak MAb RG7212, first-in-class p53-MDM2 antagonists RG7112 and RG7388 currently under clinical investigation, and the marketed BRAFV600 inhibitor vemurafenib (Zelboraf) for the treatment of melanoma. Dr. Packman's laboratory also focused on modulation of dose, schedule, and combination therapy to optimize tumor apoptotic response while limiting drug toxicity. Their work provided the basis for clinical investigation of the dose-dense regimen for the marketed drug capecitabine (Xeloda) in breast and colorectal cancer, as well as intermittent schedules for p53-MDM2 antagonist RG7388 under clinical investigation in acute myeloid leukemia (AML) and prostate cancer.

Kathryn has published over 40 peer-reviewed research articles and 6 patents. She also served as an Adjunct Professor in the Graduate School of Biomedical Sciences at the Rutgers New Jersey Medical and Dental School for 10 years. Dr. Packman earned her BSc. Degree in Biology at the State University of New York at Geneseo, and a Ph.D. in Cellular and Molecular Biology at the University of Notre Dame.

Joe Whalen, MBA

Senior Vice President, Business Development & Alliance Management
Horizon Pharma

Joe Whalen has more than 20 years of experience in the healthcare industry, leading and supporting transactions involving licensing, acquisitions, and strategic alliances. Joe joined Horizon Pharma in April of 2010 and has led or supported many of Horizon's acquisitions, helping to grow Horizon from a company of about 20 employees and no sales to over 850 employees and over $750 million in net sales. Recent transactions include Horizon's acquisitions of Crealta Holdings LLC for $510 million and PENNSAID® 2% for $45 million. He also led the out licensing of LODOTRA® and DUEXIS® ex-U.S. and has supported Horizon's IPO and other fund raising activities.

Prior to Horizon, he was at Baxter Healthcare where he led and supported a number of transactions as part of Baxter's Medication Delivery business. Joe worked at Searle prior to Baxter where his experience included various finance roles supporting business development, European operations, U.S. marketing, and R&D.

He earned a MBA from the University of Illinois and Bachelor's degree from the University of Notre Dame.